Abstract
No-reflow phenomenon is a consequence of percutaneous coronary intervention (PCI) which arises most of the time in the setting of myocardial infarction, but can be also the consequence of PCI in stable angina patients (rotatablator ablation technique or angioplasty in saphenous vein grafts). In this review, we summarize two ways of treating the noreflow according to the current literature. First through the pharmacological approach where several compounds have been assessed like adenosine, nitruprusside, verapamil, nicorandil, dipyridamole, epinephrine or cyclosporine. Second through the mechanical approach where few strategies have been examined like intra-aortic ballon pumping or postconditioning. Finally, we provide an algorithm for treating a no-reflow even though no studies showed a beneficial effect in terms of clinical endpoints.
Keywords: No-reflow, slow-flow, myocardial infarction, reperfusion
Current Vascular Pharmacology
Title:Myocardial No-Reflow Treatment
Volume: 11 Issue: 2
Author(s): Olivier Muller, Catalina Trana and Eric Eeckhout
Affiliation:
Keywords: No-reflow, slow-flow, myocardial infarction, reperfusion
Abstract: No-reflow phenomenon is a consequence of percutaneous coronary intervention (PCI) which arises most of the time in the setting of myocardial infarction, but can be also the consequence of PCI in stable angina patients (rotatablator ablation technique or angioplasty in saphenous vein grafts). In this review, we summarize two ways of treating the noreflow according to the current literature. First through the pharmacological approach where several compounds have been assessed like adenosine, nitruprusside, verapamil, nicorandil, dipyridamole, epinephrine or cyclosporine. Second through the mechanical approach where few strategies have been examined like intra-aortic ballon pumping or postconditioning. Finally, we provide an algorithm for treating a no-reflow even though no studies showed a beneficial effect in terms of clinical endpoints.
Export Options
About this article
Cite this article as:
Muller Olivier, Trana Catalina and Eeckhout Eric, Myocardial No-Reflow Treatment, Current Vascular Pharmacology 2013; 11 (2) . https://dx.doi.org/10.2174/1570161111311020015
DOI https://dx.doi.org/10.2174/1570161111311020015 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacology, Efficacy and Safety of Felodipine with a Focus on Hypertension and Angina Pectoris
Current Drug Safety History and Global Status of the New Coronavirus Covid-2019 and Aspects of Previous Infections of SARS-CoV and MERS-CoV: A Systematic Review
Coronaviruses Chronic Kidney Disease and Urological Disorders: An Overview
Current Signal Transduction Therapy Preface
Cardiovascular & Hematological Disorders-Drug Targets Lymphatic Delivery of Anti-HIV Drug Nanoparticles
Recent Patents on Nanotechnology The Cannabinoid CB2 Receptor as a Target for Inflammation-Dependent Neurodegeneration
Current Neuropharmacology Thrombin Inhibitors and Anti-Factor Xa Agents in the Treatment of Arterial Occlusion
Current Drug Targets Dabigatran - Metabolism, Pharmacologic Properties and Drug Interactions
Current Drug Metabolism Targeting FoxO1 for Hypertriglyceridemia
Current Drug Targets Potential Therapeutic Effects of Exogenous Ketone Supplementation for Type 2 Diabetes: A Review
Current Pharmaceutical Design Mn (III) Tetrakis (4-Benzoic Acid) Porphyrin Protects Against Neuronal and Glial Oxidative Stress and Death After Spinal Cord Injury
CNS & Neurological Disorders - Drug Targets Laparoscopic Surgery for Pheochromocytoma and Paraganglioma Removal: A Retrospective Analysis of Anaesthetic Management
Current Hypertension Reviews Editorial: “Ah, Wherefore with Infection Should he Live?”: Microbial Virulence Factors in Diabetic Foot Ulceration
Current Vascular Pharmacology Energy-Sensing Pathways in Ischemia: The Counterbalance Between AMPK and mTORC
Current Pharmaceutical Design Bioinformatics Tools for Mass Spectroscopy-Based Metabolomic Data Processing and Analysis
Current Bioinformatics Exploring the Role of Antioxidants to Combat Oxidative Stress in Malaria Parasites
Current Topics in Medicinal Chemistry MicroRNA-582-5p Reduces Propofol-induced Apoptosis in Developing Neurons by Targeting ROCK1
Current Neurovascular Research Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Current Pharmaceutical Design Impact of Dietary Fats on Brain Functions
Current Neuropharmacology Effect of Cardioembolic Etiology on Intravenous Thrombolysis Efficacy for Acute Ischemic Stroke
Current Neurovascular Research